NWPharmaTech’s CHR-P programme is developing NWPT-SM32300, an investigational oral cannabidiol formulation, for people experiencing symptoms associated with a clinical high risk of psychosis. The programme is led by Professor Scott Woods as CHR-P programme lead in an individual scientific capacity. See Team for affiliation notes.

Conceptual illustration of the investigational softgel presentation — not evidence of CHR-P efficacy.

The planned Phase 2B study is designed to evaluate dose response, symptoms, safety and tolerability, and to inform the next stage of development. The proposed design includes approximately 328 participants receiving placebo or one of three daily doses over 12 weeks, with follow-up at week 16.

Effectiveness in this population has not been established. Study initiation remains subject to funding, finalisation of the protocol package, and applicable approvals. Primary endpoint details are still being finalised by the clinical and statistical team.

What this note is — and is not

  • Is: a public overview of the planned study’s purpose and proposed scale.
  • Is not: a claim that recruitment has begun, that regulators have approved a final protocol, or that prevention of psychosis has been demonstrated.

For more detail, see the Programme page (including expandable study design), the public synopsis, and the evidence library.